Gallium Ga-68 Gozetotide Patent Expiration

Gallium Ga-68 Gozetotide is used for detecting prostate cancer lesions in men through positron emission tomography after radiolabeling with gallium-68. It was first introduced by Univ California Los Angeles in its drug Gallium Ga 68 Gozetotide on Dec 1, 2020. Other drugs containing Gallium Ga-68 Gozetotide are Illuccix, Locametz. 4 different companies have introduced drugs containing Gallium Ga-68 Gozetotide.


Gallium Ga-68 Gozetotide Patents

Given below is the list of patents protecting Gallium Ga-68 Gozetotide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Illuccix US11027031 Kit for radiolabelling Jul 28, 2035 Telix
Locametz US11369590 PSMA binding ligand-linker conjugates and methods for using Aug 15, 2028 Novartis